Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway
Open accessAbstract
The development of murine plasma cell tumors induced by raf/myc containing retroviruses is facilitated by T cells and completely dependent on IL-6. To determine whether kinases with differing specificities reflect alternative biochemical pathways in B cell tumorigenesis, we have employed an abl/myc containing retrovirus to assess neoplastic development. In contrast with raf/myc, abl/myc disease is T cell and IL-6 independent. An examination of the IL-6 signal transduction pathway reveals that this pathway, as defined by activation of Stat3, is inducible by IL-6 in raf/myc tumors but constitutively activated in abl/myc tumors. These findings provide a mechanism for the derivation of cytokine-independent plasma cell tumors and suggest that both IL-6-dependent and independent tumors may arise in vivo depending on the particular mutational events incurred during tumorigenesis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Either or both STAT3 and NF-κB are activated in cells transformed with HTLV-1, v-src, abl, bcr-abl or v-eyk.
“Additionally, either or both are activated in cells transformed with HTLV-1 (311), v-src (312), abl (313), bcr-abl or v-eyk (314).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [313]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- [1]1. Akira, S ∙ Nishio, Y ∙ Inoue, M ... Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway Cell. 1994; 77:63-71
Cited by
Sorted by citations
Jaks and STATs: biological implications.
Leonard, W., & O'Shea, J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,939 · see citing works
Self-citationIL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453 · see citing works
“Additionally, either or both are activated in cells transformed with HTLV-1 (311), v-src (312), abl (313), bcr-abl or v-eyk (314).”
BackgroundHirano, T., Ishihara, K., & Hibi, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203551 · Cited by 1,276 · see citing works
“STAT3 activation is required for transformation with v-src (Bromberg et al., 1998; Turkson et al., 1998) and is also implicated in v-abl-induced plasmacytomagenesis (Danial et al., 1998; Hilbert et al., 1996).”
BackgroundInfluentialThe roles of IL‐17A in inflammatory immune responses and host defense against pathogens
Iwakura, Y., Nakae, S., Saijo, S., & Ishigame, H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00699.x · Cited by 517 · see citing works
Synergistic Roles for Pim-1 and c-Myc in STAT3-Mediated Cell Cycle Progression and Antiapoptosis
Shirogane, T., Fukada, T., Müller, J. M. M., Shima, D. T., Hibi, M., & Hirano, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80145-4 · Cited by 427 · see citing works
“Upon stimulation by these et al., 1995; Hilbert et al., 1996; Migone et al., 1995;cytokines, gp130 forms a homodimer and activates the Turkson et al., 1998; Yu et al., 1995).”
BackgroundFunctional Roles of STAT Family Proteins: Lessons from Knockout Mice
Akira, S. (1999) · Stem Cells · doi:10.1002/stem.170138 · Cited by 349 · see citing works
STAT family of transcription factors in cytokine-mediated biological responses
Takeda, K., & Akira, S. (2000) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00005-8 · Cited by 310 · see citing works
Skinnider, B., Elia, A., Gascoyne, R. D., Patterson, B. J., Trümper, L. H. P., Kapp, U., & Mak, T. W. (2002) · Blood · doi:10.1182/blood.v99.2.618 · Cited by 290 · see citing works
STAT3 Acts as a Co-activator of Glucocorticoid Receptor Signaling
Zhang, Z., Jones, S. A., Hagood, J. S., Fuentes, N. L., & Fuller, G. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.49.30607 · Cited by 240 · see citing works
Insulin-like growth factor I is a dual effector of multiple myeloma cell growth.
Ge, N., & Rudikoff, S. (2000) · Blood · doi:10.1182/blood.v96.8.2856.h8002856_2856_2861 · Cited by 192
Self-citationde Vos, J., Thykjaer, T., Tarte, K., Ensslen, M., Raynaud, P., Requirand, G., Pellet, F., Pantesco, V., Rème, T., Jourdan, M., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205868 · Cited by 174
“As a potential link between ABL and gp130 IL-6 transducer pathways through STAT3 phosphorylation was suggested in murine ABL/myc plasma cell tumors (Hilbert et al., 1996), we evaluated the combined effect of STI 571 and anti-IL-6 antibodies on myeloma cell proliferation.”
BackgroundKarras, J., Wang, Z.-H., Huo, L., Howard, R., Frank, D., & Rothstein, T. (1997) · Journal of Experimental Medicine · doi:10.1084/jem.185.6.1035 · Cited by 160 · see citing works
Interleukin-6 Signal Transduction and Lymphocyte Function
Horn, F., Henze, C., & Heidrich, K. (2000) · Immunobiology · doi:10.1016/s0171-2985(00)80061-3 · Cited by 129 · see citing works
Loss of PTEN expression leading to high Akt activation in human multiple myelomas.
Hyun, T. S., Yam, A., Pece, S., Xie, X., Zhang, J., Miki, T., Gutkind, J., & Li, W.-Q. (2000) · Blood · doi:10.1182/blood.v96.10.3560.h8003560_3560_3568 · Cited by 133
STAT Signaling in the Pathogenesis and Treatment of Cancer
Frank, D. A. (1999) · Molecular Medicine · doi:10.1007/bf03403538 · Cited by 116 · see citing works
IL-6 transgenic mouse model for extraosseous plasmacytoma
Kovalchuk, A., Kim, J.-S., Park, S. S., Coleman, A., Ward, J., Morse, H., Kishimoto, T., Potter, M., & Janz, S. (2002) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.022643999 · Cited by 127 · see citing works
Signaling Pathways Activated by Oncogenic Forms of Abl Tyrosine Kinase
Zou, X., & Calame, K. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18141 · Cited by 104 · see citing works
Schatz, J., Horwitz, S., Teruya-Feldstein, J., Lunning, M., Viale, A., Huberman, K., Socci, N., Lailler, N., Heguy, A., Dolgalev, I., et al. (2014) · Leukemia · doi:10.1038/leu.2014.261 · Cited by 75 · see citing works
StAT signaling in cancer: insights into pathogenesis and treatment strategies.
Frank, D. (2003) · Cancer treatment and research · doi:10.1007/0-306-48158-8_11 · Cited by 49
“Myeloma cells often become independent of IL-6, though this generally occurs concomitant with the constitutive activation of STAT3, presumably through other pathways (Catlett-Falcone et al., 1999; Hilbert, Migone, Kopf, Leonard, & Rudikoff, 1996; Rawat et al., 2000).”
Backgroundc-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells.
Allen, J. C., Talab, F., Zuzel, M., Lin, K., & Slupsky, J. (2010) · Blood · doi:10.1182/blood-2010-08-301176 · Cited by 46
Ascherman, D., Migone, T., Friedmann, M., & Leonard, W. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.13.8704 · Cited by 41
Self-citationBaughn, L. B., di Liberto, M., Niesvizky, R., Cho, H., Jayabalan, D., Lane, J. M., Liu, F., & Chen-Kiang, S. (2009) · Journal of Immunology · doi:10.4049/jimmunol.0713726 · Cited by 40 · see citing works
Inhibition of interleukin‐5 with a monoclonal antibody attenuates allergic inflammation
Danzig, M., & Cuss, F. (1997) · Allergy. European Journal of Allergy and Clinical Immunology · doi:10.1111/j.1398-9995.1997.tb02149.x · Cited by 35
O'Shea, J., Notarangelo, L., Johnston, J., & Candotti, F. (1997) · Journal of Clinical Immunology · doi:10.1023/a:1027388508570 · Cited by 31 · see citing works
“Some examples of this include transformation with v-src, abl/myc, and spleen focus forming virus (204-207).”
BackgroundHarder, H., Eucker, J., Zang, C., Possinger, K., Müller-Höcker, J., Beutler, E., & Petrides, P. (2000) · Annals of Hematology · doi:10.1007/s002770000202 · Cited by 29
STAT3 exerts two-way regulation in the biological effects of IL-6 in M1 leukemia cells
Zhang, J., Shen, B., Li, Y., & Sun, Y. (2001) · Leukemia Research · doi:10.1016/s0145-2126(00)00157-0 · Cited by 25 · see citing works
Crowder, C., Kopantzev, E., Williams, K., Lengel, C., Miki, T., & Rudikoff, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206180 · Cited by 24 · see citing works
“The critical role of Stat3 in IL-6 signaling is further demonstrated by observations indicating that constitutive Stat3 phosphorylation is associated with IL-6-independent plasma cell growth (Hilbert et al., 1996; Rawat et al., 2000).”
BackgroundSelf-citationThe tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice
Rosean, T. R., Tompkins, V., Olivier, A., Sompallae, R., Norian, L., Morse, H. C., Waldschmidt, T., & Janz, S. (2014) · Leukemia · doi:10.1038/leu.2014.260 · Cited by 22 · see citing works
Kovalchuk, A., Kishimoto, T., & Janz, S. (2000) · Leukemia · doi:10.1038/sj.leu.2401767 · Cited by 21 · see citing works
Therapeutic effects of antibodies t interleukin‐5
Cuss, F. M. (1998) · Allergy. European Journal of Allergy and Clinical Immunology · doi:10.1111/j.1398-9995.1998.tb04947.x · Cited by 13 · see citing works
Noronha, E., Sterling, K. H., & Calame, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306629200 · Cited by 11 · see citing works
Hematologic neoplasias and acromegaly
Barbosa, F. R. P., Vieira, L., Lima, G. A. B., Wildemberg, L., Portugal, R., & Gadelha, M. (2011) · Pituitary · doi:10.1007/s11102-009-0176-0 · Cited by 10 · see citing works
“The role of IL-6 in MM has been demonstrated in IL-6 null mice, which normally fail to develop plasma cell tumors [35, 36], though these tumors can be induced in an IL-6-independent manner by selected agents [ 37 ].”
BackgroundMazzera, L., Abeltino, M., Lombardi, G., Cantoni, A. M., Ria, R., Ricca, M., Saltarella, I., Naponelli, V., Rizzi, F., Perris, R., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.208280 · Cited by 7 · see citing works
Duarte, R., & Frank, D. (2000) · Medicina Clínica · doi:10.1016/s0025-7753(00)71252-8 · Cited by 7 · see citing works
Poli, V., & Maritano, D. (2003) · doi:10.1007/978-1-59259-405-4_13 · Cited by 7
Role of IL-6 and CD23 in the resistance to growth arrest and apoptosis in LCL41 B lymphoma cells.
Militi, S., Chiapparino, C., Testa, U., Carminati, P., Santis, R. D., & Serlupi-Crescenzi, O. (2005) · Cytokine · doi:10.1016/j.cyto.2005.05.007 · Cited by 2
gp130-mediated signalling as a therapeutic target
Ohtani, T., Ishihara, K., Atsumi, T., Yoshida, Y., Nishida, K., Narimatsu, M., Shirogane, T., Hibi, M., & Hirano, T. (2000) · Emerging Therapeutic Targets · doi:10.1517/14728222.4.4.459 · Cited by 2 · see citing works
“The involvement of STAT proteins in cell growth is supported by the observation that STATs are constitutively activated in cells transformed with human T-cell leukaemia virus I (HTLV-I) [105], v-src [106,107], abl [108,109], bcr-abl [110], eyk [111] and active Gαo [112], and in some multiple myeloma cells [113].”
BackgroundJAK/STAT Signaling in Myeloid Cells
Priceman, S. J., Deng, J., Jove, R., & Yu, H. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00026-9
- Authors
- Hilbert, D. M., Migone, T.-S., Kopf, M., Leonard, W. J., & Rudikoff, S.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Rudikoff, Stuart
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 1996-07
- Volume
- 5
- Issue
- 1
- Pages
- 81-89
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W1983257767
- Cited by
- 40
- References
- 0
- Citations by year
- 2020: 1 · 2019: 1 · 2014: 1 · 2013: 1
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- c-Abl, Raf kinase, B-cell malignancies, plasma cell tumor, IL-6 signaling, STAT3 activation, MYC oncogene, retroviral oncogenesis, T cell dependence, tumorigenicity
- MeSH terms
- Animals, Base Sequence, Mice, Inbred BALB C, Mice, Inbred DBA, Mice, Nude, Molecular Sequence Data, Phenotype, Plasmacytoma, Retroviridae Infections, Tumor Virus Infections, Signal Transduction, Interleukin-6, Genes, abl, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
